Merck & Co ends deal with SurModics
This article was originally published in Scrip
Merck & Cohas discontinued its licence and research collaboration with the US-based drug delivery companySurModics, following a strategic review of its business and product development portfolio. SurModics said that the decision was not based on any concerns over the safety or efficacy of its I-vation TA, the I-vation platform or any of its other sustained drug delivery systems. SurModics is currently in licensing discussions with other companies and said that it would continue to work with its partners to meet their required timelines in developing products for the treatment of eye diseases.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.